Human papillomavirus: problems and prospects for women's reproductive health (systematic review).

Objective: Aim: To consider the specific activity of drops and suppositories of PROTEFLAZID® at the stage of preclinical study, to assess the effectiveness and safety of use in clinical practice in papillomavirus-associated diseases of the female reproductive system..

Patients and methods: Materials and Methods: Analysis of scientific publications on the treatment of palilomavirus infection with PROTEFLAZID® in women over the past decade.

Results: Results: Medicines have a direct antiviral effect on papillomaviruses. Clinical trials have shown that the drugs are safe and effective agents for the treatment of papillomavirus-associated CIN1 and CIN2 in the mode of simultaneous systemic and topical use. The proposed scheme is a promising method of treating class I-II neoplasias in women of reproductive age, as it avoids cervical damage, early and late complications and preserves female reproductive function.

Conclusion: Conclusions: PROTEFLAZID® (drops and suppositories) are safe and effective etiopathogenetic drugs for the systemic and topical treatment of papillomavirusassociated diseases in women. Medicines demonstrate the potential for the prevention of cervical cancer, as they allow organ-preserving treatment in women of reproductive age as a guarantee of future motherhood.